Scaffold Therapeutics

About Scaffold Therapeutics

Scaffold Therapeutics develops RNA-targeted cancer therapies using machine learning to analyze and regulate RNA modifications that affect stability, transcription, and degradation. Their platform accelerates drug discovery across oncology and neurodegenerative diseases by providing insights into pathway biology and aligning experimental research with clinical objectives.

```xml <problem> Traditional drug discovery processes for cancer and neurodegenerative diseases are slow and inefficient, often failing to fully leverage the complexities of RNA biology. Understanding and manipulating RNA modifications, which influence stability, transcription, and degradation, remains a significant challenge in developing effective therapies. </problem> <solution> Scaffold Therapeutics has developed a drug discovery platform that uses machine learning to analyze and regulate RNA modifications, enabling the development of RNA-targeted therapies for oncology and neurodegenerative diseases. The platform provides insights into pathway biology and aligns experimental research with clinical objectives, accelerating the identification of promising drug candidates. By focusing on RNA modifications that control stability, transcription, and degradation, Scaffold Therapeutics aims to create a pipeline of assets targeting clinically validated and first-in-class biology. The platform helps to overcome the limitations of traditional methods by providing a more comprehensive understanding of the transcriptome. </solution> <features> - Machine learning-driven analysis of RNA modifications - Identification of novel drug targets in oncology and neurodegenerative diseases - Regulation of RNA stability, transcription, and degradation - Platform designed to accelerate drug discovery - Focus on clinically validated and first-in-class biology </features> <target_audience> The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapies for cancer and neurodegenerative diseases. </target_audience> ```

What does Scaffold Therapeutics do?

Scaffold Therapeutics develops RNA-targeted cancer therapies using machine learning to analyze and regulate RNA modifications that affect stability, transcription, and degradation. Their platform accelerates drug discovery across oncology and neurodegenerative diseases by providing insights into pathway biology and aligning experimental research with clinical objectives.

Where is Scaffold Therapeutics located?

Scaffold Therapeutics is based in Boston, United States.

When was Scaffold Therapeutics founded?

Scaffold Therapeutics was founded in 2022.

How much funding has Scaffold Therapeutics raised?

Scaffold Therapeutics has raised 2150000.

Location
Boston, United States
Founded
2022
Funding
2150000
Employees
3 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

Scaffold Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Scaffold Therapeutics develops RNA-targeted cancer therapies using machine learning to analyze and regulate RNA modifications that affect stability, transcription, and degradation. Their platform accelerates drug discovery across oncology and neurodegenerative diseases by providing insights into pathway biology and aligning experimental research with clinical objectives.

scaffoldtx.com500+
cb
Crunchbase
Founded 2022Boston, United States

Funding

$

Estimated Funding

$2M+

Team (<5)

No team information available.

Company Description

Problem

Traditional drug discovery processes for cancer and neurodegenerative diseases are slow and inefficient, often failing to fully leverage the complexities of RNA biology. Understanding and manipulating RNA modifications, which influence stability, transcription, and degradation, remains a significant challenge in developing effective therapies.

Solution

Scaffold Therapeutics has developed a drug discovery platform that uses machine learning to analyze and regulate RNA modifications, enabling the development of RNA-targeted therapies for oncology and neurodegenerative diseases. The platform provides insights into pathway biology and aligns experimental research with clinical objectives, accelerating the identification of promising drug candidates. By focusing on RNA modifications that control stability, transcription, and degradation, Scaffold Therapeutics aims to create a pipeline of assets targeting clinically validated and first-in-class biology. The platform helps to overcome the limitations of traditional methods by providing a more comprehensive understanding of the transcriptome.

Features

Machine learning-driven analysis of RNA modifications

Identification of novel drug targets in oncology and neurodegenerative diseases

Regulation of RNA stability, transcription, and degradation

Platform designed to accelerate drug discovery

Focus on clinically validated and first-in-class biology

Target Audience

The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapies for cancer and neurodegenerative diseases.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.